Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nontuberculous Mycobacterial Disease Clear all
Completed Phase 2 Interventional Results available

Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

NCT01315236
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
Liposomal amikacin for inhalation (LAI), placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 6, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

NCT00002170
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
San Diego, California • Torrance, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

NCT05730283
View directory record Official record
Conditions
Ototoxicity, Drug-Induced
Interventions
ORC-13661, Placebo
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 6, 2026, 4:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

NCT02372383
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ethambutol, Rifampin, Azithromycin, Pancrelipase
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 6, 2026, 4:06 AM EDT
Completed Phase 3 Interventional

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677569
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS)
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
90
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 6, 2026, 4:06 AM EDT
Completed Phase 3 Interventional

Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex

NCT03164291
View directory record Official record
Conditions
Nontuberculous Mycobacterial Infections
Interventions
Rifabutin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1984 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 6, 2026, 4:06 AM EDT
Enrolling by invitation No phase listed Observational

Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria

NCT05686837
View directory record Official record
Conditions
Cystic Fibrosis, Nontuberculous Mycobacterial Pulmonary Infection
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Month to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Denver, Colorado • Baltimore, Maryland • Austin, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 6, 2026, 4:06 AM EDT
Completed No phase listed Observational

The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients

NCT00000860
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 4:06 AM EDT
Completed Phase 4 Interventional

Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease

NCT00598962
View directory record Official record
Conditions
Mycobacterium Avium Complex
Interventions
Azithromycin, Rifabutin/rifampin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 6, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

NCT00002192
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Rifapentine, Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Anderson Clinical Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 4:06 AM EDT
Recruiting Phase 2 Interventional

Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)

NCT07094711
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous
Interventions
Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine, preservative-free saline
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 6, 2026, 4:06 AM EDT
Completed No phase listed Observational

A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients

NCT00000907
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 6, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

NCT00002267
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 4:06 AM EDT
Completed Phase 3 Interventional

Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS

NCT00001047
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Clofazimine, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 6, 2026, 4:06 AM EDT
Completed Phase 2 Interventional

A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS

NCT00000644
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clarithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2011 · Synced Oct 6, 2026, 4:06 AM EDT
Completed Phase 1 Interventional

Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV

NCT00002104
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections, Tuberculosis, Mycobacterium Infection
Interventions
Thalidomide
Drug
Lead sponsor
Aaron Diamond AIDS Research Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 4:06 AM EDT
Recruiting No phase listed Observational

Biomarkers of Phage Treatment Response in NTM and Other Infections

NCT07076238
View directory record Official record
Conditions
Nontuberculous Mycobacterial Lung Disease
Interventions
Bacteriophage Treatment
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 6, 2026, 4:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History Study of GATA2 Deficiency and Related Disorders

NCT01905826
View directory record Official record
Conditions
GATA2 Deficiency
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 6, 2026, 4:06 AM EDT
Recruiting No phase listed Observational

Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)

NCT06155747
View directory record Official record
Conditions
Nontuberculous Mycobacterial Pulmonary Infection, Outbreak Investigation, Healthcare Associated Infection, Mycobacterium Infections
Interventions
Epidemiologic investigation
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Month to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 6, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Dapsone Drug Concentrations

NCT01165840
View directory record Official record
Conditions
Obesity, Leprosy, Tuberculosis
Interventions
Dapsone
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 6, 2026, 4:06 AM EDT
Terminated Phase 2 Interventional

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease

NCT04154826
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
Recombinant human interleukin-7
Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 6, 2026, 4:06 AM EDT
Active, not recruiting Phase 2 Interventional

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)

NCT02968212
View directory record Official record
Conditions
Mycobacterium Avium Complex
Interventions
Clofazimine, sugar pill
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Denver, Colorado • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 6, 2026, 4:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Study of Mycobacterial Infections

NCT00018044
View directory record Official record
Conditions
Mycobacterium Infections
Interventions
Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 6, 2026, 4:06 AM EDT